You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

Patent: 9,169,470

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,169,470
Title:Methods and compositions for generating bioactive assemblies of increased complexity and uses
Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
Inventor(s): Chang; Chien-Hsing (Downingtown, PA), Goldenberg; David M. (Mendham, NJ), McBride; William J. (Boonton, NJ), Rossi; Edmund A. (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc. (Morris Plains, NJ)
Application Number:14/488,921
Patent Claims:see list of patent claims

Details for Patent 9,169,470

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-10-19 RX search
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-10-19 RX search
Genentech XOLAIR omalizumab VIAL 103976 001 2003-06-20   Start Trial IBC Pharmaceuticals, Inc. (Morris Plains, NJ) 2025-10-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.